Similar articles

• Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

  Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LW, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW. Gomez HL, et al. J Clin Oncol. 2008 Jun 20;26(18):2999-3005. doi: 10.1200/JCO.2007.14.0590. Epub 2008 May 5. J Clin Oncol. 2008. PMID: 18458039 Clinical Trial.
• Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

  Cameron DA, Stein S. Cameron DA, et al. Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Nat Clin Pract Oncol. 2008. PMID: 18594499 Review.
• Lapatinib-associated toxicity and practical management recommendations.

  Moy B, Goss PE. Moy B, et al. Oncologist. 2007 Jul;12(7):756-65. doi: 10.1634/theoncologist.12-7-756. Oncologist. 2007. PMID: 17673607 Review.
• Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

  Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Robidoux A, et al. Lancet Oncol. 2013 Nov;14(12):1183-92. doi: 10.1016/S1470-2045(13)70411-X. Epub 2013 Oct 4. Lancet Oncol. 2013. PMID: 24095300 Clinical Trial.
• Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.

  Choi HD, Chang MJ. Choi HD, et al. Breast Cancer Res Treat. 2017 Dec;166(3):927-936. doi: 10.1007/s10549-017-4460-9. Epub 2017 Aug 19. Breast Cancer Res Treat. 2017. PMID: 28825152